Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2870198 | 1.00 | PTGER4 (0.48) | PTGER4LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL300478 | 0.89 | FABP4 (0.50) | PTGER4SLC2A1FABP4MEN1KMT2A | |
| SCHEMBL182893 | 0.88 | FABP4 (0.49) | PTGER4LMNASLC2A1FABP4MEN1 | |
| SCHEMBL5807508 | 0.86 | MAPT (0.46) | PTGER4LMNAHTTSMN1; SMN2HTR2C | |
| SCHEMBL5811567 | 0.84 | CYP2C9 (0.48) | LMNASMN1; SMN2MAPTSIGMAR1 | |
| SCHEMBL4218086 | 0.82 | FABP4 (0.50) | PTGER4LMNAHTTSMN1; SMN2FABP4 | |
| SCHEMBL5806383 | 0.80 | FABP4 (0.49) | PTGER4LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL10216949 | 0.79 | MEN1 (0.48) | LMNAHTTSMN1; SMN2SLC2A1FABP4 | |
| SCHEMBL4920523 | 0.79 | CNR2 (0.46) | PTGER4MAPTTP53MEN1KMT2A | |
| SCHEMBL4906436 | 0.77 | CNR2 (0.46) | PTGER4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | claimed |
| EP-2139328-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-01-06 | — | — | EP | claimed |
| EP-2139326-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | Janssen Pharmaceutica, N.V. (BE) | 2010-01-06 | — | — | EP | claimed |
| WO-2008115705-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | WO | claimed |
| WO-2008115671-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | WO | claimed |
| US-20080234347-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | US | claimed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | claimed |
| EP-2139328-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008115705-A2 | HEXAHYDRO-CYCLOHEPTAPYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | PTGER4 568/4885LMNA 4644/4885HTT 440/4885 |
| US-20080234347-A1 | METHOD FOR TREATING CB2 RECEPTOR MEDIATED PAIN | CNR2, CNR1, NPY4R | PTGER4 89/4885LMNA 3769/4885HTT 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.